BBIO Acoramidis claims reversal in ATTR-CM progression and function
BBIO says Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline in ATTR-CM, and increases days alive and free from hospitalization.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.